These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36175810)

  • 1. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
    Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
    Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
    Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
    J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of the motor function measure in patients with spinal muscular atrophy.
    Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C;
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
    Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
    Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 8. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.
    Zhang Q; Hong Y; Brusa C; Scoto M; Cornell N; Patel P; Baranello G; Muntoni F; Zhou H
    Sci Rep; 2024 Oct; 14(1):23491. PubMed ID: 39379509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criterion validity of the spatial exploration test of upper limb mobility to evaluate the active horizontal workspace of children with spinal muscular atrophy.
    Pruvost S; Gomez Garcia de la Banda M; Quijano Roy S; Izedaren F; Roche N; Pouplin S
    Disabil Rehabil; 2024 Feb; 46(3):575-580. PubMed ID: 36650958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
    Panicucci C; Sahin E; Bartolucci M; Casalini S; Brolatti N; Pedemonte M; Baratto S; Pintus S; Principi E; D'Amico A; Pane M; Sframeli M; Messina S; Albamonte E; Sansone VA; Mercuri E; Bertini E; Sezerman U; Petretto A; Bruno C
    Cell Mol Life Sci; 2024 Sep; 81(1):393. PubMed ID: 39254732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.
    Gómez-García de la Banda M; Amaddeo A; Khirani S; Pruvost S; Barnerias C; Dabaj I; Bénézit A; Durigneux J; Carlier RY; Desguerre I; Quijano-Roy S; Fauroux B
    Pediatr Pulmonol; 2021 Jan; 56(1):299-306. PubMed ID: 33118682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen treatment in adults with severe spinal muscular atrophy: A real-life retrospective observational cohort study.
    Lefeuvre C; Brisset M; Sarlon M; Petit N; Orlikowski D; Clair B; Thiry T; Carlier RY; Prigent H; Nicolas G; Annane D; Laforet P; Pouplin S
    Rev Neurol (Paris); 2022 Mar; 178(3):234-240. PubMed ID: 35000792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
    Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
    Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
    de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
    J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
    Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
    Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
    Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
    Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.